Why the study?
TCAR was developed to mitigate risks associated with carotid endarterectomy and transfemoral stenting and is used in high- and standard-risk patients, prompting this report of outcomes from a large single-institution cohort.
Cohort (n=1,000)
No
Answers are grounded in this paper and cite their sources.
In a large, single-center cohort, TCAR demonstrated high technical success (98%) and a low 30-day composite perioperative morbidity rate of 2.9%.
BACKGROUND: Transcarotid artery revascularization (TCAR) was developed to mitigate risks associated with both carotid endarterectomy and transfemoral carotid artery stenting. It is being performed in both high- and standard-risk patients. We report outcomes from the largest single-institution consecutive TCAR cohort to date. METHODS: A retrospective review was performed from a prospectively maintained database capturing all consecutive TCAR procedures performed across a large health system between September 2017 and May 2025. Demographics, perioperative variables, and short- and long-term outcomes were analyzed. A multivariable logistic regression was used to identify predictors of perioperative stroke or death within 30 days. RESULTS: A total of 1,000 TCAR procedures were performed by 23 surgeons. The mean age was 74 years. In all, 31% of patients presented with symptomatic stenosis. Technical success was achieved in 98%. Thirty-day stroke, death, and myocardial infarction occurred at 1.9%, 1.0%, and 0.2%, respectively, for a composite rate of 2.9%. The median length of stay was 1 day. At a mean follow-up of 18 months, ipsilateral stroke occurred in 3.4%, restenosis/reintervention in 1.7%, and all-cause mortality in 6.6%. Multivariable analysis identified prior stroke (odds ratio [OR] 2.4, P < 0.001) and chronic obstructive pulmonary disease (OR 1.7, P = 0.011) as independent predictors of perioperative stroke/death. Protective factors included clopidogrel use (OR 0.45, P = 0.014) and intraoperative administration of protamine (OR 0.47, P = 0.011). CONCLUSION: TCAR demonstrated high technical success, low perioperative morbidity, and favorable long-term outcomes in both high- and standard-risk patients. Optimal medical management and risk stratification by comorbidity and prior neurologic events improve outcomes. Randomized trials are needed to better define the roles of TCAR and carotid endarterectomy.
No takes yet. Share an insight, caveat, or question.
Dodwad et al. (2025) conducted a cohort in Carotid artery stenosis (n=1,000). Transcarotid artery revascularization (TCAR) was evaluated on 30-day composite of stroke, death, and myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: